Predictors of uncontrolled hyperlipidaemia in high-risk ambulatory patients in primary care

References

• . Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106: 3143–421
   PubMed Web of Science ®Google Scholar
• World Health Organization. European health for all database. Updated January 2003 http://www.euro.who.int/hfad
   Google Scholar
• D'Agostino Sr RB, Grundy S, Sullivan LM, . Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001;286: 180–7
   PubMed Web of Science ®Google Scholar
• Conroy RM, Pyorala K, Fitzgerald AP, . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24: 987–1003
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110: 227–39
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Ronnemaa T, . Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339: 229–34
   PubMed Web of Science ®Google Scholar
• Juutilainen A, Lehto S, Ronnemaa T, . Type 2 diabetes as a ’coronary heart disease equivalent‚: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005;28: 2901–7
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Allen J, Blair SN, . AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113: 2363–72
   PubMed Web of Science ®Google Scholar
• Geller JC, Cassens S, Brosz M, . Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. Eur Heart J 2007doi:10.1093/eurheartj/ehm520
   PubMedGoogle Scholar
• Pearson TA, Denke MA, McBride PE, . A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80: 587–95
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Johnson-Levonas AO, . Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44: 467–94
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF, . Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002;90: 1092–7
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T, . Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24: 729–41
   PubMed Web of Science ®Google Scholar
• Migoya EM, Bergman A, Hreniuk D, . Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects. Int J Clin Pharmacol Ther 2006;44: 83–92
   PubMed Web of Science ®Google Scholar
• Pearson GJ, Francis GA, Romney JS, . The clinical effect and tolerability of ezetimibe in high-risk patients managed in a specialty cardiovascular risk reduction clinic. Can J Cardiol 2006;22: 939–45
   PubMed Web of Science ®Google Scholar
• Ose L, Shah A, Davies MJ, . Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin 2006;22: 823–35
   PubMed Web of Science ®Google Scholar
• Simons L, Tonkon M, Masana L, . Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin 2004;20: 1437–45
   PubMed Web of Science ®Google Scholar
• Hildemann SK, Barho C, Karmann B, . Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 2007;23: 713–19
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection E, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285: 2486–97
   PubMed Web of Science ®Google Scholar
• Gagne C, Bays HE, Weiss SR, . Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90: 1084–91
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, . Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23: 2009–26
   PubMed Web of Science ®Google Scholar
• Sharma A, Wittchen H, Kirch W, . High prevalence and poor control of hypertension in primary care: cross sectional study. J Hypertens 2004;22: 479–86
   PubMed Web of Science ®Google Scholar
• Koro CE, Bowlin SJ, Bourgeois N, . Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27: 17–20
   PubMed Web of Science ®Google Scholar
• Snow V, Aronson MD, Hornbake ER, . Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2004;140: 644–9
   PubMed Web of Science ®Google Scholar
• Costa J, Borges M, David C, . Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332: 1115–18
   PubMed Web of Science ®Google Scholar
• Knopp RH, Dujovne CA, Le Beaut A, . Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract 2003;57: 363–8
   PubMed Web of Science ®Google Scholar
• Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract 2006;60: 914–21
   PubMed Web of Science ®Google Scholar
• Galin ID, Smith DA. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) Study. Am Heart J 2006;151: e1
   PubMedGoogle Scholar
• Pittrow D, Kirch W, Bramlage P, . Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004;60: 135–42
   PubMed Web of Science ®Google Scholar
• Pittrow D, Stalla GK, Zeiher AM, . Prävalenz, medikamentöse Behandlung und Einstellung des Diabetes mellitus in der Hausarztpraxis. Med Klin (Munich) 2006;101: 135–644
   Google Scholar
• Yan AT, Yan RT, Tan M, . Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006;119: 676–83
   PubMed Web of Science ®Google Scholar
• Pearson TA, Laurora I, Chu H, . The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160: 459–67
   PubMed Web of Science ®Google Scholar
• Mosca L, Merz NB, Blumenthal RS, . Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation 2005;111: 488–93
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maki KC, Pearson TA, . Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol 2005;96: 556–63
   PubMed Web of Science ®Google Scholar
• Knight EL, Bohn RL, Wang PS, . Predictors of Uncontrolled Hypertension in Ambulatory Patients. Hypertension 2001;38: 809–814
   PubMed Web of Science ®Google Scholar